Literature DB >> 2858513

Neuroleptics and beta-carbolines displace (3H)Imipramine from its binding sites in human and rat tissues.

H Rommelspacher, S Strauss.   

Abstract

Most investigations dealing with the pharmacological characterization of (3H)imipramine binding sites focus on tricyclic antidepressants (TCA). This approach seemed to be justified since imipramine belongs to that chemical group. Langer and coworkers, however, introduced a tetrahydro-beta-carboline (TH beta C) as a possible endogenous ligand. Thus, the high affinity of imipramine towards the binding sites might not be due to its special chemical structure but due to its tricyclic nature. In the present paper the structure-activity-relationships of neuroleptics and beta-carbolines were investigated and compared with that of tricyclic antidepressants. Among the tricyclic neuroleptics those with an electron attracting substituent (-Cl) exerted highest affinity. The effect was attenuated by a long, cyclic side chain. The affinity of tricyclic neuroleptics was only slightly weaker than that of 6-Meo-TH beta C the suggested endogenous ligand. The experiments with other TH beta Cs supported the observation that an electron attracting substituent increases the affinity of a compound to the (3H)imipramine binding sites. Comparison of the binding characteristics of (3H)imipramine to membranes of human brain and thrombocytes as well as those of rat brain and thrombocytes revealed no differences among both species. Furthermore, the displacing potencies of neuroleptics were very similar with only slightly more activity in human tissue. As a methodological aspect the applicability of the "Lowry" method to determine the protein concentration is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858513     DOI: 10.1007/bf01253051

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  17 in total

1.  Synthetic experiments in the group of hypotensive alkaloids. XXI.Chemistry of 1,2,3,4- tetrahydronorharmane-1-carboxylic acid and derivatives.

Authors:  Z J VEJDELEK; V TRCKA; M PROTIVA
Journal:  J Med Pharm Chem       Date:  1961-05-18

2.  Demonstration of specific "high affinity" binding sites for [3H] imipramine on human platelets.

Authors:  S M Paul; M Rehavi; P Skolnick; F K Goodwin
Journal:  Life Sci       Date:  1980-03-24       Impact factor: 5.037

3.  Substituted tetrahydro-beta-carbolines are possible candidates as endogenous ligand of the [3H]imipramine recognition site.

Authors:  S Z Langer; R Raisman; L Tahraoui; B Scatton; R Niddam; C R Lee; Y Claustre
Journal:  Eur J Pharmacol       Date:  1984-02-10       Impact factor: 4.432

4.  3H-imipramine binding in platelets: influence of varying proportions of intact platelets in membrane preparations on binding.

Authors:  W Friedl; P Propping; B Weck
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  Molecular mechanisms in the action of imipramine.

Authors:  E Costa; D M Chuang; M L Barbaccia; O Gandolfi
Journal:  Experientia       Date:  1983-08-15

6.  Demonstration of specific high affinity binding sites for [3H] imipramine in human brain.

Authors:  M Rehavi; S M Paul; P Skolnick; F K Goodwin
Journal:  Life Sci       Date:  1980-06-30       Impact factor: 5.037

7.  Specific tricyclic antidepressant binding sites in rat brain.

Authors:  R Raisman; M Briley; S Z Langer
Journal:  Nature       Date:  1979-09-13       Impact factor: 49.962

8.  Specific 3H-imipramine binding in human platelets. Influence of age and sex.

Authors:  S Z Langer; M S Briley; R Raisman; J F Henry; P L Morselli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-09       Impact factor: 3.000

9.  Human platelet imipramine recognition sites: biochemical and pharmacological characterization.

Authors:  L P Wennogle; B Beer; L R Meyerson
Journal:  Pharmacol Biochem Behav       Date:  1981-12       Impact factor: 3.533

Review 10.  On the mode of action of imipramine: relationship between serotonergic axon terminal function and down-regulation of beta-adrenergic receptors.

Authors:  M L Barbaccia; N Brunello; D M Chuang; E Costa
Journal:  Neuropharmacology       Date:  1983-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.